Adenocarcinoma of the prostate in Iceland: A population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987

Scandinavian Journal of Urology and Nephrology

Volumn 40, Issue 4, 2006, Pages 265-271

  Jonsson, E ^a   Sigbjarnarson, H P ^a   Tomasson, J ^a   Benediktsdottir, K R ^a,b   Tryggvadottir, L ^c   Hrafnkelsson, J ^a   Olafsdottir, E J ^c   Tulinius, H ^c   Jonasson, J G ^a,b,c  

^a LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^b UNIVERSITY OF ICELAND   (Iceland)

^c ICELANDIC CANCER REGISTRY   (Iceland)

Author keywords

Adenocarcinoma; Death certificates; Population study; Prostate neoplasia; Survival

Indexed keywords

ANTIANDROGEN;

ACCURACY; ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; CANCER DIAGNOSIS; CANCER GRADING; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; DEATH CERTIFICATE; FOLLOW UP; GLEASON SCORE; HISTOLOGY; HUMAN; HUMAN TISSUE; ICELAND; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METASTASIS; POPULATION RESEARCH; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE ADENOCARCINOMA; PROSTATE TUMOR; PROSTATECTOMY; REVIEW; SURVIVAL TIME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; FOLLOW-UP STUDIES; HUMANS; ICELAND; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROSTATIC NEOPLASMS; REGISTRIES; SURVIVAL ANALYSIS;

EID: 33747616846     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.1080/00365590600750110     Document Type: Review

References (26)

1. International Union Against Cancer. TNM classification of malignant tumours, 5th ed. Sobin LH, Wittekind Ch., editors. New York: Wiley-Liss; 1997.
2. Gleason DF, Mellinger GT, and The Veterans Administration Cooperative Urological Research Group. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111:58-64.
3. Khalifa NM, Jarman WD. A study of 48 cases of incidental carcinoma of the prostate followed 10 years or longer. J Urol 1976;116:329-31.
4. Barnes R, Hirst A, Rosenquist R. Early carcinoma of the prostate: comparison of stages A and B. J Urol 1976;115:404-5.
5. Golimbu M, Morales P. Stage A 2 prostatic carcinoma. Should staging system be reclassified? Urology 1979;13:592-96.
6. Moller B, Fekjaer H, Hakulinen T, Tryggvadottir L, Storm HH, Talback M, et al. Prediction of cancer incidence in the Nordic countries up to the year 2020 [Review]. Eur J Cancer Prev 2002;(11 Suppl 1):S1-96.
7. Tretli S, Engeland A, Haldorsen T, Hakulinen T, Horte LG, Luostarinen T, et al. Prostate cancer-look to Denmark? J Natl Cancer Inst 1996;88:128.
8. Brasso K, Iversen P. Prostate cancer in Denmark. Incidence, morbidity and mortality. Scand J Urol Nephrol Suppl 1999;203:29-33.
9. Sheldon CA, Williams RD, Fraley EE. Incidental carcinoma of the prostate: a review of the literature and critical reappraisal of classification. J Urol 1980;124:626-31.
10. Rohr LR. Incidental adenocarcinoma in transurethral resection of the prostate. Am J Surg Pathol 1987;11:53-8.
11. Merrill RM, Feuer EJ, Warren JL, Schussler N, Stephenson RA. Role of transurethral resection of the prostate in population-based prostate cancer incidence rates. Am J Epidemiol 1999;150:848-60.
12. Jack S, Geirsson G. Changes in treatment and cost of benign prostatic hyperplasia. Icelandic Med J 2001;87:213-8.
13. Blomqvist P, Ekbom A, Carlsson P, Ahlstrand C, Johansson JE. Benign prostatic hyperplasia in Sweden 1987 to 1994: changing patterns of treatment, changing patterns of cost. Urology ;50 1987;1997:214-20.
14. Brasso K, Friis S, Kruger SK, Jörgensen T, Iversen P. Prostate cancer in Denmark: a 50-year population-based study. Urology 1998;51:590-4.
15. Garraway WM, Alexander FE. Prostate disease: epidemiology, natural history and demographic shifts. Br J Urol 1997;79(Suppl 2):3-8.
16. Brewster DH, Fraser LA, Harris V, Black RJ. Rising incidence of prostate cancer in Scotland: increased risk or increased detection? BJU Int 2000;85:463-73.
17. Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P. Prognostic value of the Gleason score in prostate cancer. BJU Int 2002;89:538-42.
18. Lau WK, Blute ML, Bostwick DG, Weaver AL, Sebo TJ, Zincke H. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4. J Urol 2001;166:1692-7.
19. Merrill RM, Bird JS. Effect of young age on prostate cancer survival: a population-based assessment (United States). Cancer Causes Control 2002;13:435-43.
20. Adami HO, Norlén BJ, Malker B, Meirik O. Long-term survival in prostatic carcinoma, with special reference to age as a prognostic factor. Scand J Urol Nephrol 1986;20:107-12.
21. Bill-Axelson A, Holmberg L, Ruutu M, Haggmann M, Andersson SO, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352:1977-84.
22. Johansson JE, Holmberg L, Johansson S, Bergström R, Adami HO. Fifteen-year survival in prostate cancer; a prospective, population-based study in Sweden. JAMA 1997;277:467-71.
23. Sandblom G, Dufmats M, Varenhorst E. Long-term survival in a Swedish population-based cohort of men with prostate cancer. Urology 2000;56:442-7.
24. Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, et al. Natural history of early, localized prostate cancer. JAMA 2004;291:2713-19.
25. Aus G, Hugosson J, Norlén L. Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol 1995;154:460-5.
26. Brasso K, Friis S, Juel K, Jörgensen T, Iversen P. Mortality of patients with clinically localized prostate cancer treated with observation for 10 years or longer: a population based registry study. J Urol 1999;161:524-8.